Nika PHARMACEUTICALS, Inc. (NIKA) intrinsic value & 10-year financials
Nika PHARMACEUTICALS, Inc. (NIKA) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 7 fiscal years revenue reached to $1.1K, with an average return on invested capital of 2371.7%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.41
- Market cap
- $429.5M
- Revenue (FY2025)
- $1.1K
- ROIC (10-yr avg)
- 2371.7%
- Free cash flow (FY2025)
- —
NIKA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $1.1K | -$76.4K | $0.00 | — | -6821.3% | -437.1% |
| FY2024 | $0 | -$95.8K | $0.00 | — | — | -1208.7% |
| FY2023 | $0 | -$64.8K | $0.00 | — | — | 130.4% |
| FY2022 | $0 | -$3.2M | $0.00 | — | — | 15555.0% |
| FY2021 | $0 | -$14.7K | $0.00 | — | — | 90.5% |
| FY2020 | — | -$8.9K | — | — | — | 100.0% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
NIKA PHARMACEUTICALS, INC revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
NIKA PHARMACEUTICALS, INC has earned high returns on invested capital, averaging 76.7% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
NIKA PHARMACEUTICALS, INC capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
NIKA PHARMACEUTICALS, INC is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.